Antibiotics

BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics

Retrieved on: 
Mercoledì, Marzo 13, 2024

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.
  • As part of these new kit configurations, total workflow time has been reduced to under eight hours for both products.
  • “These new core kits provide researchers with an optimized and validated workflow that delivers industry-leading single-cell multiomic performance,” said Suresh Pisharody, CEO, BioSkryb.
  • The ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit leverages its PTA-based WGA technology to couple each single cell’s whole genome with its full-length whole transcriptome.

Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay

Retrieved on: 
Martedì, Aprile 2, 2024

SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Key Points: 
  • "We are delighted to bring the experience and expertise of Broad Clinical Labs to this innovative collaboration with Quest.
  • "This type of collaboration between commercial laboratories and research institutions is vital to advance the field of genetic testing and increase utility and economic value."
  • While the ACMG recommends WGS for first-line genetic testing for intellectual disability and developmental delay, some providers continue to follow prior guidelines that recommend chromosomal microarray (CMA) as a first-line test.
  • Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 600,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease.

Second Opinion Expert Announces Strategic Relationship With Genome International

Retrieved on: 
Lunedì, Aprile 1, 2024

LOS ANGELES, April 1, 2024 /PRNewswire/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that it has entered into a strategic relationship with Genome International to provide rapid Whole Genome Interpretation (WGI™) delivered by Genome Explorer®, a comprehensive Clinical Decision Support System that brings genomic information to the point of care.

Key Points: 
  • We are proud to be part of Genome International's revolutionary effort to put the power of the genome in the hands of healthcare practitioners worldwide.
  • SOE will assist Genome International with business development and strategy, leveraging SOE's relationships and expertise.
  • Genome Explorer® provides a single unified platform for whole genome variant interpretation with high accuracy and success across diseases.
  • "We are proud to be part of Genome International's revolutionary effort to put the power of the genome in the hands of healthcare practitioners worldwide."

CosmosID Announces Collaboration with Resilient Biotics for Advanced Microbiome Exploration of the Respiratory Tract

Retrieved on: 
Giovedì, Marzo 21, 2024

DURHAM, N.C., March 21, 2024 /PRNewswire/ -- CosmosID, a renowned microbiome analytics company, is thrilled to announce a groundbreaking collaboration with Resilient Biotics, a leading microbiome platform company with a pipeline of products for maintaining respiratory tract health.

Key Points: 
  • DURHAM, N.C., March 21, 2024 /PRNewswire/ -- CosmosID, a renowned microbiome analytics company, is thrilled to announce a groundbreaking collaboration with Resilient Biotics, a leading microbiome platform company with a pipeline of products for maintaining respiratory tract health.
  • "We are excited to collaborate with CosmosID, a leader in the genomic sequencing space," said Chris Belnap, CEO of Resilient Biotics.
  • "We are honored to join forces with Resilient Biotics, a trailblazer in microbiome research," said Manoj Dadlani, president of CosmosID.
  • "Our collaboration aims to deepen our understanding of the respiratory tract's microbiome, which could redefine the future of respiratory health management.

Clinical Microbiomics adds World-Leading Expertise in Long-Read DNA & RNA Sequencing Technologies with Acquisition of DNASense ApS

Retrieved on: 
Venerdì, Marzo 1, 2024

The acquisition expands Clinical Microbiomics' expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long- read DNA- and RNA sequencing technologies to the extensive portfolio of multi-omics technologies for the microbiome field.

Key Points: 
  • The acquisition expands Clinical Microbiomics' expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long- read DNA- and RNA sequencing technologies to the extensive portfolio of multi-omics technologies for the microbiome field.
  • H. Bjørn Nielsen, CSO of Clinical Microbiomics, "DNASense is a first mover in applying long-read technology broadly across microbiome research and industrial applications.
  • Mads Søndergaard, CEO of DNASense, comments on the synergies: "Joining Clinical Microbiomics is a pivotal moment for DNASense.
  • The DNASense acquisition facilitates expansion into new applications of microbiome science to better understand diverse biological systems and ecological dynamics.

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Retrieved on: 
Giovedì, Febbraio 22, 2024

SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated infections (HAIs), which are some of the most common complications of hospital care.

Key Points: 
  • Our nanoparticle technology represents an exciting innovation that could profoundly reduce infections associated with medical devices like catheters without contributing to antibiotic resistance," said Shaun Rothwell, CEO of EVŌQ Nano.
  • By infusing EVŌQ Nano's proprietary nanoparticle, EVQ-218, throughout the polymer itself, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms.
  • EVQ-218 delivers high antimicrobial efficacy without ion emissions.6,7 Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance.
  • By incorporating antimicrobial protection into the material manufacturing process, EVŌQ Nano's technology enables the next generation of medical devices to more effectively guard against disease.

Bacteria in your gut can improve your mood − new research in mice tries to zero in on the crucial strains

Retrieved on: 
Giovedì, Febbraio 15, 2024

But can they improve your mood, too?

Key Points: 
  • But can they improve your mood, too?
  • But the short answer, according to my team’s recently published research, is likely yes.
  • The beneficial bacteria in probiotics become part of a community of other microscopic organisms living in your digestive system called the gut microbiome.

Studying mood in mice

  • So how do you measure the mood of mice?
  • We exposed them to poop from either stressed mice or normal mice by sprinkling soiled bedding in their enclosures.
  • Microbes from the donor mice started to populate the gut microbiomes of the clean mice.
  • Within a few weeks, the clean mice exposed to poop from stressed mice started to develop stress- and anxiety-like behavior, even though nothing else had changed.

Which bacteria affect mood?

  • The results of our experiments led us back to our original question: Which bacteria can change your mood?
  • In our analysis, we found that a group of bacteria called Lactobacillus was greatly reduced in the stressed mice.
  • So we had to come up with a way to test how different strains affect anxious behavior.
  • Instead of tackling this colossal task alone, we created a method that other microbiome scientists can also use to look at this group of bacteria as systematically as possible.
  • To recreate the same experimental conditions for each species of microbe, we created a group of mice with only six species of bacteria in their microbiome, the bare minimum needed for normal and healthy development, which did not include Lactobacillus.

What’s next?

  • We hope that our research will open avenues for other scientists to test different probiotics.
  • In the meantime, give the Lactobacillus in your gut some love through a healthy, probiotics-rich diet.


Andrea Merchak has received funding from the National Institutes of Health (T32 NS115657, F31 AI174782).

Global Genome Editing Market Research Report 2023-2035: Pharmaceutical Giants Expand Capabilities - WuXi AppTec and Ensoma Lead Acquisitions - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Febbraio 12, 2024

The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).

Genome Editing Market Report 2024: Technology Licensing Deals are Driving the Overall Partnership Activity - Global Industry Trends and Forecasts 2023-2035

Retrieved on: 
Mercoledì, Febbraio 7, 2024

DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).

At AGBT, Complete Genomics showcases expanded sequencing applications, talks from customers and collaborators on research powered by the DNBSEQ-T7 Sequencer

Retrieved on: 
Martedì, Febbraio 6, 2024

SAN JOSE, Calif., Feb. 6, 2024 /PRNewswire/ -- Complete Genomics, a California-based life sciences company that provides novel, comprehensive sequencing solutions, today highlighted expanded sequencing applications enabled by DNBSEQ™-T7, a leading high- throughput sequencer which will be the subject of customer talks at the Advances in Genome Biology and Technology (AGBT) General Meeting.

Key Points: 
  • After four years in the field, the DNBSEQ-T7, or the T7, remains a leading sequencer in its class, due to its speed, accuracy and flexibility.
  • The T7 enables a wide range of applications such as CompleteWGS, a novel phased genome approach, spatial transcriptomics, cf-DNA sequencing for MRD and early detection, and single cell sequencing.
  • The DNBSEQ™-T20X2 is Complete Genomics' ultra-high-throughput sequencer for the most challenging projects, delivering efficient sequencing at less than $1 per Gigabase.
  • Highly accurate base calling and robust copy number correction is ensured by our robotics-enabled fluidics, which uses whole-wafer-sized slides.